Extended Data Fig. 8: Individualized patient response to in vivo therapeutic targeting of XIAP, AURKB and KIF10. | Nature Cancer

Extended Data Fig. 8: Individualized patient response to in vivo therapeutic targeting of XIAP, AURKB and KIF10.

From: Combined inhibition of XIAP and BCL2 drives maximal therapeutic efficacy in genetically diverse aggressive acute myeloid leukemia

Extended Data Fig. 8

a,b, Individualized patient response to AZD5582-based combination therapy with (a) barasertib and (b) GSK923295 are shown. Number of PDX models generated for each patient are presented above the panels. Significance of AML cell elimination was assessed by paired two-tailed t-test (PB) and unpaired two-tailed t-test (BM, SPL). PB, peripheral blood; BM, bone marrow; SPL, spleen; Pre, pre-treatment; Post, post-treatment.

Source data

Back to article page